Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

292.77USD
2:30pm EDT
Change (% chg)

$3.65 (+1.26%)
Prev Close
$289.12
Open
$286.14
Day's High
$296.01
Day's Low
$286.05
Volume
459,979
Avg. Vol
677,409
52-wk High
$370.53
52-wk Low
$249.24

Latest Key Developments (Source: Significant Developments)

Biogen Enters Exclusive Option Agreement To Acquire TMS’ Phase 2 Asset For Acute Stroke
Thursday, 7 Jun 2018 07:30am EDT 

June 7 (Reuters) - Biogen Inc ::BIOGEN ENTERS EXCLUSIVE OPTION AGREEMENT TO ACQUIRE TMS’ PHASE 2 ASSET FOR ACUTE STROKE.BIOGEN ENTERS EXCLUSIVE OPTION AGREEMENT TO ACQUIRE TMS’ PHASE 2 ASSET FOR ACUTE STROKE.BIOGEN INC - TO PAY $4 MILLION UPFRONT AND $18 MILLION UPON EXERCISE OF OPTION, PLUS POTENTIAL MILESTONES OF UP TO $335 MILLION AND ROYALTIES.BIOGEN INC - AGREEMENT INCLUDES AN UPFRONT PAYMENT OF $4 MILLION AND AN ADDITIONAL $18 MILLION PAYMENT IF BIOGEN EXERCISES ITS OPTION.BIOGEN INC - ENTERED INTO AN EXCLUSIVE OPTION AGREEMENT WITH TMS CO., LTD. TO ACQUIRE TMS-007 AND BACKUP COMPOUNDS.  Full Article

EMA Recommends Immediate Suspension, Recall Of Multiple Sclerosis Medicine Zinbryta
Wednesday, 7 Mar 2018 05:09am EST 

March 7 (Reuters) - EU Medicines Agency::EMA RECOMMENDS IMMEDIATE SUSPENSION AND RECALL OF MULTIPLE SCLEROSIS MEDICINE ZINBRYTA.EMA RECOMMENDATION FOLLOWING 12 REPORTS OF SERIOUS INFLAMMATORY BRAIN DISORDERS WORLDWIDE, INCLUDING ENCEPHALITIS AND MENINGOENCEPHALITIS.EMA’S RECOMMENDATION TO SUSPEND ZINBRYTA AND RECALL THE PRODUCT IS BEING SENT TO THE EUROPEAN COMMISSION FOR A LEGALLY BINDING DECISION.PRELIMINARY REVIEW OF EVIDENCE INDICATES IMMUNE REACTIONS OBSERVED IN REPORTED CASES MAY BE LINKED TO USE OF ZINBRYTA‍​.  Full Article

Biogen And Abbvie Announce The Voluntary Worldwide Withdrawal Of Marketing Authorizations For Zinbryta
Friday, 2 Mar 2018 05:07am EST 

March 2 (Reuters) - Abbvie Inc ::BIOGEN AND ABBVIE ANNOUNCE THE VOLUNTARY WORLDWIDE WITHDRAWAL OF MARKETING AUTHORIZATIONS FOR ZINBRYTA® (DACLIZUMAB) FOR RELAPSING MULTIPLE SCLEROSIS.ABBVIE INC - EMA HAS INITIATED AN ARTICLE 20 REFERRAL PROCEDURE FOLLOWING REPORTS OF INFLAMMATORY ENCEPHALITIS AND MENINGOENCEPHALITIS.ABBVIE - ‍BIOGEN WILL CONTINUE TO WORK WITH REGULATORY AUTHORITIES & WITH HEALTHCARE PROVIDERS IN THEIR MANAGEMENT OF ZINBRYTA PATIENTS​.ABBVIE - GIVEN NATURE OF ADVERSE EVENTS REPORTED, CHARACTERIZING PROFILE OF ZINBRYTA TO NOT BE POSSIBLE GOING AHEAD WITH LIMITED PATIENTS BEING TREATED.ABBVIE INC - BIOGEN BELIEVES VOLUNTARY WORLDWIDE WITHDRAWAL OF ZINBRYTA "IS IN BEST INTEREST OF PATIENTS".  Full Article

Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke
Wednesday, 7 Feb 2018 07:30am EST 

Feb 7 (Reuters) - Biogen Inc ::BIOGEN REPORTS TOP-LINE RESULTS FROM PHASE 2B STUDY OF NATALIZUMAB IN ACUTE ISCHEMIC STROKE.BIOGEN INC - PRIMARY AND SECONDARY EFFICACY ENDPOINTS WERE NOT MET IN ACTION 2 STUDY.BIOGEN INC - FURTHER DEVELOPMENT OF NATALIZUMAB IN ACUTE ISCHEMIC STROKE WILL NOT BE PURSUED.BIOGEN INC - IN MIDDLE OF 2018, BIOGEN PLANS TO INITIATE A GLOBAL PHASE 3 STUDY OF BIIB093 IN INDIVIDUALS WITH LARGE HEMISPHERIC INFARCTION.BIOGEN - IN PHASE 2A ACTION STUDY, SECONDARY, EXPLORATORY ENDPOINTS SUGGESTED NATALIZUMAB TREATMENT IMPROVED CLINICAL OUTCOMES VERSUS PLACEBO (ADDS DROPPED WORDS).  Full Article

Karyopharm Announces Agreement For Biogen To Acquire KPT-350
Thursday, 25 Jan 2018 06:30am EST 

Jan 25 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM ANNOUNCES AGREEMENT FOR BIOGEN TO ACQUIRE KPT-350 FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS.KARYOPHARM THERAPEUTICS INC - DEAL VALUED AT UP TO $217 MILLION.KARYOPHARM THERAPEUTICS - ‍BIOGEN IS ACQUIRING KPT-350 AND OTHER ASSETS TARGETING CERTAIN NEUROLOGICAL CONDITIONS, INCLUDING ALS.KARYOPHARM - DEAL INCLUDES $10 MILLION UPFRONT PAYMENT TO KARYOPHARM, AND POTENTIAL $207 MILLION IN FUTURE MILESTONES, PLUS ROYALTIES.KARYOPHARM - CO ALSO ELIGIBLE TO GET TIERED ROYALTIES FROM BIOGEN THAT REACH LOW DOUBLE DIGITS BASED ON FUTURE NET SALES OF SOME PRODUCT CANDIDATES.  Full Article

Biogen Responds To Coverage Recommendation By The Canadian Drug Expert Committee (Cdec) For Spinraza
Friday, 22 Dec 2017 04:11pm EST 

Dec 22 (Reuters) - Biogen Inc ::BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA).BIOGEN - CDEC'S RECOMMENDATION DISAPPOINTS AS CLINICAL CRITERIA, CONDITIONS LIMIT PATIENTS WITH SMA THAT COULD POTENTIALLY BENEFIT FROM SPINRAZA.  Full Article

Biogen, Ionis Collaborate To Identify Novel Therapies To Treat Spinal Muscular Atrophy
Tuesday, 19 Dec 2017 04:06pm EST 

Dec 19 (Reuters) - Biogen Inc ::BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY.BIOGEN WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF THE COLLABORATION.‍IONIS WILL RECEIVE A $25 MILLION UPFRONT PAYMENT AND WILL EARN DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS FROM BIOGEN.BIOGEN WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND COMMERCIALIZATION.ON COMMERCIALIZATION OF NOVEL THERAPIES TO TREAT SPINAL MUSCULAR ATROPHY​, BIOGEN TO PAY IONIS PERFORMANCE MILESTONES, ROYALTIES ON NET SALES.  Full Article

Sarissa Capital Management's Alexander​ ‍Denner Buys 30,000 Shares Of Biogen's Common Stock
Thursday, 30 Nov 2017 07:40am EST 

Nov 30 (Reuters) - Biogen Inc ::SARISSA CAPITAL MANAGEMENT'S ALEXANDER​ ‍DENNER REPORTS PURCHASE OF 30,000 SHARES OF BIOGEN INC'S COMMON STOCK BETWEEN NOV 28-29 - SEC FILING.  Full Article

Biogen appoints Jeff Capello as executive vice president and chief financial officer
Tuesday, 21 Nov 2017 07:30am EST 

Nov 21 (Reuters) - Biogen Inc ::Appoints Jeff Capello as executive vice president and chief financial officer.Says Capello's appointment as CFO effective as of Dec 11, 2017​.  Full Article

Acorda announces royalty monetization transactions for $53 mln
Friday, 17 Nov 2017 07:02am EST 

Nov 17 (Reuters) - Acorda Therapeutics Inc :Acorda announces royalty monetization transactions for $53 million.Acorda Therapeutics - A $40 million royalty monetization with healthcare royalty partners and a $13 million royalty monetization with H. Lundbeck A/S​.Acorda Therapeutics Inc - ‍ In return for payment to Acorda, HCR obtains right to receive royalty revenue on Fampyra payable by Biogen.Acorda - ‍H. Lundbeck, Acorda amended license agreement for selincro to eliminate future royalty, milestone obligations on sale of Selincro outside U.S..Acorda Therapeutics Inc - Transaction does not include potential future milestones to be paid by Biogen​.  Full Article

Samsung BioLogics said JV partner Biogen to exercise option by late June

SEOUL, May 18 Samsung BioLogics said on Friday that its joint venture partner Biogen would exercise its call option to increase its stake to 50 pct minus one share in Samsung Bioepis.